Views & Analysis Nanomedicine: delivering on its promise? The nanomedicines market is worth billions. Tarun Pandotra reviews developments in the sector.
Views & Analysis Data: underpinning health R&D Big data initiatives positioning the UK as a desirable location for R&D.
News Ultragenyx to slash costs after Angelman trial failure Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
